Form 4: Tharimmune Director Leonard Mazur Acquires Options

Director Leonard Mazur of Tharimmune, Inc. reports the acquisition of options to purchase 2,353 shares of common stock on August 9, 2024.

Summary

• On August 9, 2024, Leonard Mazur, a director of Tharimmune, Inc., acquired options to purchase 2,353 shares of the company's common stock.
• The options were granted pursuant to the company's 2023 Omnibus Equity Incentive Plan.
• The exercise price of the options is $2.925.
• The options vest in 12 equal monthly installments, beginning on the grant date, and expire on August 9, 2034.
• Following the transaction, Mazur directly owns 27,353 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of options to a director is a standard practice and generally viewed as a positive sign of aligning interests with shareholders.

Positives

• The granting of options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Industry Context

This is a standard practice for incentivizing company directors and aligning their interests with shareholders. Equity grants are common in the biotech industry to attract and retain talent.

Comparison to Industry Standards

• Equity compensation for directors is a common practice across the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options and restricted stock units to incentivize their board members.
• The vesting schedule of 12 months is fairly standard, aligning with typical industry practices for equity grants.

Stakeholder Impact

• Shareholders may view this as a positive sign, aligning the director's interests with the company's success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

Tharimmune, Leonard Mazur, options, director, Form 4, equity incentive plan, common stock, beneficial ownership